NATCO Pharma Limited (NATCOPHARM) Fair Value & Analysis
Healthcare · IN · Market cap ₹167B
Fair value as of: Jul 3, 2026
From 26 valuation models · updated today
Share price −0.3% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹790.18 – ₹1,206 · fair‑value band ₹846.76 – ₹2,139 · the ₹931.40 price screens below the ₹1,139 fair value. As of Jul 3, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
NATCO Pharma Limited (NATCOPHARM) currently trades at ₹931.40, while our model-based Fair Value estimate is ₹1,139 — implying the stock looks roughly 22.2% undervalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
Over the trailing twelve months, NATCO Pharma Limited generated revenue of ₹40.8B at a net margin of 34.8%. Revenue declined 39.6% year over year. It earns a return on equity of 16.9%. Net debt stands at ₹5.2B. Fundamentals as of Jul 3, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 3, 2026. TTM = trailing twelve months.
About the company
NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, the company offers neurology, cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company provides agro chemicals and biological pest management solutions for management …
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
NATCO Pharma Limited reported revenue of ₹40.8B in FY2026 versus ₹19.5B in FY2022, a compound +20.3%/yr. Reported net income was ₹14.2B in FY2026, compounding +70.0%/yr from FY2022.
Is NATCOPHARM fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 3, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is NATCO Pharma Limited (NATCOPHARM) undervalued?
What is the fair value of NATCOPHARM?
What is the quality score of NATCOPHARM?
What is the revenue of NATCO Pharma Limited (NATCOPHARM)?
What is the net profit margin of NATCOPHARM?
Does NATCO Pharma Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.